281 related articles for article (PubMed ID: 18762167)
1. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
2. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
Huarte N; Lorizate M; Kunert R; Nieva JL
FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
[TBL] [Abstract][Full Text] [Related]
4. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
[TBL] [Abstract][Full Text] [Related]
6. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
7. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
Law M; Cardoso RM; Wilson IA; Burton DR
J Virol; 2007 Apr; 81(8):4272-85. PubMed ID: 17267498
[TBL] [Abstract][Full Text] [Related]
8. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
9. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA
Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805
[TBL] [Abstract][Full Text] [Related]
11. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
Matyas GR; Wieczorek L; Beck Z; Ochsenbauer-Jambor C; Kappes JC; Michael NL; Polonis VR; Alving CR
AIDS; 2009 Oct; 23(16):2069-77. PubMed ID: 19710597
[TBL] [Abstract][Full Text] [Related]
14. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
Liu Z; Chen YH
J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
[TBL] [Abstract][Full Text] [Related]
16. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
17. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.
Benen TD; Tonks P; Kliche A; Kapzan R; Heeney JL; Wagner R
J Biomed Sci; 2014 Aug; 21(1):79. PubMed ID: 25160824
[TBL] [Abstract][Full Text] [Related]
18. Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.
Melnychuk L; Ajamian L; Jean-Pierre P; Liang J; Gheorghe R; Wainberg MA; Zaharatos GJ
Vaccine; 2017 May; 35(20):2736-2744. PubMed ID: 28392143
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
Dong XN; Chen YH
Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
[TBL] [Abstract][Full Text] [Related]
20. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
